6533b7d3fe1ef96bd1261470
RESEARCH PRODUCT
Proline-Based Allosteric Inhibitors of Zika and Dengue Virus NS2B/NS3 Proteases
Fabian BarthelsMelissa ImmerheiserMichael BasicNathalie JungJochen BodemAndrea GellertChristian KerstenTanja SchirmeisterWerner KieferUte A. HellmichUte A. HellmichStefan HammerschmidtEberhard HildtFabian ElgnerMaike WindbergsBenedikt MilliesUlrike GöppelFranziska Von Hammersteinsubject
ProteasesProlineProtein ConformationAllosteric regulationViral Nonstructural ProteinsDengue virusmedicine.disease_causeAntiviral Agents01 natural sciencesDengueSerineStructure-Activity RelationshipViral Proteins03 medical and health sciencesAllosteric RegulationCatalytic DomainDrug DiscoverymedicineHumansStructure–activity relationshipProtease Inhibitors030304 developmental biology0303 health sciencesNS3Ligand efficiencyZika Virus InfectionChemistryProtease bindingSerine EndopeptidasesZika VirusDengue Virus0104 chemical sciencesMolecular Docking Simulation010404 medicinal & biomolecular chemistryBiochemistryA549 CellsMolecular MedicineAllosteric SitePeptide HydrolasesProtein Bindingdescription
The NS2B/NS3 serine proteases of the Zika and Dengue flaviviruses are attractive targets for the development of antiviral drugs. We report the synthesis and evaluation of a new, proline-based compound class that displays allosteric inhibition of both proteases. The structural features relevant for protease binding and inhibition were determined to establish them as new lead compounds for flaviviral inhibitors. Based on our structure-activity relationship studies, the molecules were further optimized, leading to inhibitors with submicromolar IC50 values and improved lipophilic ligand efficiency. The allosteric binding site in the proteases was probed using mutagenesis and covalent modification of the obtained cysteine mutants with maleimides, followed by computational elucidation of the possible binding modes. In infected cells, antiviral activity against Dengue virus serotype 2 using prodrugs of the inhibitors was observed. In summary, a novel inhibitor scaffold targeting an allosteric site shared between flaviviral NS2B/NS3 proteases is presented whose efficacy is demonstrated in vitro and in cellulo.
year | journal | country | edition | language |
---|---|---|---|---|
2019-11-27 | Journal of Medicinal Chemistry |